Abstract

Lornoxicam is a NSAID having oxicam class mainly prescribed in the treatment of osteoarthritis and rheumatoid arthritis. NSAID have the potential to relieve the pain and inflammation without the immunosuppressive and metabolic side effects associated with corticosteroids. Generally the classification of NSAID is applied to drugs that inhibit one or more steps in the metabolism of Arachidonic Acid (AA). In general, NSAID do not inhibit lipoxygenase formation or the formation of other inflammatory mediators. Due to its more biological half-life i.e. 3-5 hrs. in India, the dosage form is available in 8-16 mg, it can be increased upto 24 mg/day if necessary. The main objectives of present investigation are to confirm the drug by various analytical techniques, to study the drug excipients compatibility, to avoid the dose as well as the frequency of the dosage form and to perform the stability. The tablet can be developed with the combination of HPMC K 100M and Ethyl Cellulose as a matrix former. Lornoxicam is NSAID that has numerous functions in the body. It can be absorbed rapidly and completely from gastrointestinal track after the oral administration. Absolute bioavailability of Lornoxicam is 90-100%. No first pass effect is observed. It is found in the plasma in the unchanged form and as its hydroxylated metabolite. The hydroxylated metabolite exhibits no pharmacological activity. CYP2C3 has been shown to be the primary enzyme responsible for the biotransformation of Lornoxicam. Approximately 2/3 part of Lornoxicam is eliminated via the liver and 1/3 via the kidneys as inactive substance. Lornoxicam inhibits the production of prostaglandins by inhibiting the action of cyclooxygenase, which regulates the conversion of Arachidonic Acid to Prostaglandins. Lornoxicam mainly prescribed in the treatment of osteoarthritis and rheumatoid arthritis, and also in the management of ankylosing spondylitis, acute sciatica and low back pain. Keywords: Lornoxicam, Sustained release, matrix.

Authors and Affiliations